219 related articles for article (PubMed ID: 33669329)
1. Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström's Macroglobulinemia.
Kaiser LM; Harms M; Sauter D; Rawat VPS; Glitscher M; Hildt E; Tews D; Hunter Z; Münch J; Buske C
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33669329
[TBL] [Abstract][Full Text] [Related]
2. EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models.
Sagini MN; Zepp M; Eyol E; Ali DM; Gromova S; Dahlmann M; Behrens D; Groeschel C; Tischmeier L; Hoffmann J; Berger MR; Forssmann WG
Peptides; 2024 May; 175():171111. PubMed ID: 38036098
[TBL] [Abstract][Full Text] [Related]
3. An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation.
Harms M; Habib MMW; Nemska S; Nicolò A; Gilg A; Preising N; Sokkar P; Carmignani S; Raasholm M; Weidinger G; Kizilsavas G; Wagner M; Ständker L; Abadi AH; Jumaa H; Kirchhoff F; Frossard N; Sanchez-Garcia E; Münch J
Acta Pharm Sin B; 2021 Sep; 11(9):2694-2708. PubMed ID: 34589390
[TBL] [Abstract][Full Text] [Related]
4. Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists.
Sokkar P; Harms M; Stürzel C; Gilg A; Kizilsavas G; Raasholm M; Preising N; Wagner M; Kirchhoff F; Ständker L; Weidinger G; Mayer B; Münch J; Sanchez-Garcia E
Commun Biol; 2021 Sep; 4(1):1113. PubMed ID: 34552197
[TBL] [Abstract][Full Text] [Related]
5. Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia.
Papanota AM; Ntanasis-Stathopoulos I; Kastritis E; Dimopoulos MA; Gavriatopoulou M
J Blood Med; 2019; 10():291-300. PubMed ID: 31695539
[TBL] [Abstract][Full Text] [Related]
6. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.
Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Patterson CJ; Tsakmaklis N; Kanan S; Rodig S; Castillo JJ; Treon SP
Leukemia; 2015 Jan; 29(1):169-76. PubMed ID: 24912431
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib in previously treated Waldenström's macroglobulinemia.
Treon SP; Tripsas CK; Meid K; Warren D; Varma G; Green R; Argyropoulos KV; Yang G; Cao Y; Xu L; Patterson CJ; Rodig S; Zehnder JL; Aster JC; Harris NL; Kanan S; Ghobrial I; Castillo JJ; Laubach JP; Hunter ZR; Salman Z; Li J; Cheng M; Clow F; Graef T; Palomba ML; Advani RH
N Engl J Med; 2015 Apr; 372(15):1430-40. PubMed ID: 25853747
[TBL] [Abstract][Full Text] [Related]
8. Proteolytic processing of human serum albumin generates EPI-X4, an endogenous antagonist of CXCR4.
Zirafi O; Hermann PC; Münch J
J Leukoc Biol; 2016 Jun; 99(6):863-8. PubMed ID: 26965637
[TBL] [Abstract][Full Text] [Related]
9. Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia.
Grunenberg A; Buske C
Future Oncol; 2019 Aug; 15(23):2687-2697. PubMed ID: 31184501
[TBL] [Abstract][Full Text] [Related]
10. Conformational States of the CXCR4 Inhibitor Peptide EPI-X4-A Theoretical Analysis.
Jung CK; Münch J; Jacob T
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003419
[TBL] [Abstract][Full Text] [Related]
11. Targeting cell adhesion and homing as strategy to cure Waldenström's macroglobulinemia.
Pals ST; Kersten MJ; Spaargaren M
Best Pract Res Clin Haematol; 2016 Jun; 29(2):161-168. PubMed ID: 27825462
[TBL] [Abstract][Full Text] [Related]
12. CXCR4 in Waldenström's Macroglobulinema: chances and challenges.
Kaiser LM; Hunter ZR; Treon SP; Buske C
Leukemia; 2021 Feb; 35(2):333-345. PubMed ID: 33273682
[TBL] [Abstract][Full Text] [Related]
13. Advanced EPI-X4 Derivatives Covalently Bind Human Serum Albumin Resulting in Prolonged Plasma Stability.
Rodríguez-Alfonso A; Heck A; Ruiz-Blanco YB; Gilg A; Ständker L; Kuan SL; Weil T; Sanchez-Garcia E; Wiese S; Münch J; Harms M
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499357
[TBL] [Abstract][Full Text] [Related]
14. Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations.
Gilg A; Harms M; Olari LR; Urbanowitz AK; Bonig H; Münch J
J Transl Med; 2021 May; 19(1):190. PubMed ID: 33941197
[TBL] [Abstract][Full Text] [Related]
15. Development of N-Terminally Modified Variants of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability.
Harms M; Fabech Hansson R; Gilg A; Almeida-Hernández Y; Löffler J; Rodríguez-Alfonso A; Habib MMW; Albers D; Ahmed NS; Abadi AH; Winter G; Rasche V; Beer AJ; Weidinger G; Preising N; Ständker L; Wiese S; Sanchez-Garcia E; Zelikin AN; Münch J
J Med Chem; 2023 Nov; 66(22):15189-15204. PubMed ID: 37940118
[TBL] [Abstract][Full Text] [Related]
16. Neutralising properties of peptides derived from CXCR4 extracellular loops towards CXCL12 binding and HIV-1 infection.
Chevigné A; Fievez V; Szpakowska M; Fischer A; Counson M; Plesséria JM; Schmit JC; Deroo S
Biochim Biophys Acta; 2014 May; 1843(5):1031-41. PubMed ID: 24480462
[TBL] [Abstract][Full Text] [Related]
17. Current and novel BTK inhibitors in Waldenström's macroglobulinemia.
Ntanasis-Stathopoulos I; Gavriatopoulou M; Fotiou D; Dimopoulos MA
Ther Adv Hematol; 2021; 12():2040620721989586. PubMed ID: 33613931
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic algorithm of Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma in Japan].
Sekiguchi N
Rinsho Ketsueki; 2021; 62(8):1139-1148. PubMed ID: 34497201
[TBL] [Abstract][Full Text] [Related]
19. X4 HIV-1 induces neuroblastoma cell death by interference with CXCL12/CXCR4 interaction.
Hatse S; Bridger G; de Clercq E; Schols D
Cell Mol Biol (Noisy-le-grand); 2003; 49 Online Pub():OL443-52. PubMed ID: 14995074
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.
Mailankody S; Landgren O
Best Pract Res Clin Haematol; 2016 Jun; 29(2):187-193. PubMed ID: 27825465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]